Chronic obstructive pulmonary disease (COPD) is characterized by persistent and progressive airflow limitation, and a new study examined the factors responsible for a high St George’s Respiratory Questionnaire for COPD based on severity of airflow limitation.
Chronic obstructive pulmonary disease (COPD) is characterized by persistent and progressive airflow limitation, and a new study examined the factors responsible for a high St George’s Respiratory Questionnaire for COPD (SGRQ-C) based on severity of airflow limitation.
The study, published in the International Journal of COPD, included 1264 patients who were categorized into 2 groups based on the severity of airflow limitation: mild-to-moderate COPD and severe-to-very severe COPD.
“The substantial symptomatic burden of COPD reduces physical and psychological functioning, ultimately decreasing health-related quality of life (HRQoL),” explained the authors.
They sought to analyze the SGRQ-C, which is used to grade symptoms, to identify factors associated with a high score in patients with stable COPD based on the severity of airflow limitation.
The study selected patients in the Korean COPD Subgroup Study cohort and recorded a variety of data, including age, sex, height, weight, smoking status, comorbidities, 6-minute walk distance, cough, sputum, and SGRQ-C score. Of the 902 patients who had mild-to-moderate COPD, 534 (59.2%) had a high SGRQ-C score, and of the 362 patients with severe-to-very severe COPD, 261 (80.4%) had a high SGRQ-C score.
Compared with patients with a low SGRQ-C score, patients with mild-to-moderate COPD and a high score were more likely to be less educated, have more comorbidities, and suffer from more respiratory symptoms, such as cough, sputum, and dyspnea. These patients also had a “significantly lower level” of exercise capacity as determined by the 6-minute walk distance.
Patients with severe-to-very severe COPD and a high score were more likely to have a lower body mass index, a history of pneumonia, osteoporosis, and respiratory symptoms, such as cough, sputum, and dyspnea. Similar to patients with mild-to-moderate COPD, this group had a significantly shorter 6-minute walk distances compared with similar patients with a low SGRQ-C score. No comorbidities were associated with a high score for this group.
Overall, the researchers found a negative correlation between HRQoL and severity of airflow limitation. The fact that only respiratory symptoms were significantly associated with a high SGRQ-C score “indicates the need for an improved management strategy for relieving respiratory symptoms in COPD patients with poor HRQoL,” the authors concluded.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
2 Commerce Drive
Cranbury, NJ 08512